Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...

Hims & Hers Health, Inc. investors will be delighted, with the company turning in some strong numbers with its latest results. It was overall a positive result, with revenues beat ...

Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...

Most investors would look at an earnings announcement as a past event, connecting the current price action in the stock and reacting to the results as something that cannot be taken advantage of, ...

TD Cowen analyst Jonna Kim maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of ...

Seaport Global analyst Aaron Kessler maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

Headlines,Hims & Hers Health Surpasses Earnings Expectations,Strong Revenue Growth Drives Positive Stock Movement,Analysts ...